This article is more than 5 years old. Information may no longer be current.

Allegro enrolls patients in phase 2 trial of Luminate for DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allegro Ophthalmics announced that it is enrolling 150 patients in a phase 2 trial to assess Luminate, previously known as ALG-1001, for patients with diabetic macular edema.

The phase 2 study is a randomized, controlled, double-masked, multicenter, dose-ranging trial to evaluate the safety and efficacy of intravitreal injections of Luminate compared to current therapies for DME, according to the press release.

Patients will be randomized into one of five treatment groups that include three Luminate groups (1.0 mg, 2.0 mg or 3.0 mg), a bevacizumab (Genentech) group and a focal laser photocoagulation group. All patients will return for examinations every 4 weeks for 6 months.

In previous clinical studies, Luminate has been effective as monotherapy to reduce the burden of intravitreal injections, according to the company.

Luminate treats vitreoretinal diseases by targeting integrin receptors involved in cell signaling and regulation, and in the construction of new and aberrant blood vessels, according to the press release.